Saturday 17 October 2026
Export XLO’s income statement to Excel — free account
Xilio Therapeutics, Inc.
Xilio Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $43.8 million, up 589.9% from fiscal 2024. In the quarter to June 2026, revenue grew 131.2%, EPS grew 85.3% and free cash flow fell 26.2%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
8.77
0.25
−2.77%
Follow XLO
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
2.90 | 2.57 | 1.71 | 3.82 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(9.91) | (6.15) | (37.49) | (6.94) | |
P/B ratio |
2.57 | 1.90 | 2.12 | 0.00 | |
Price to Tangible BV |
2.57 | 1.90 | 2.12 | 0.00 | |
EV/Sales |
0.80 | (0.21) | (1.40) | 0.60 | |
EV/EBITDA |
0.00 | 0.28 | 1.51 | 0.00 | |
EV/Operating CF |
(0.85) | 0.20 | 12.24 | (1.12) | |
EV/FCF |
(0.84) | 0.20 | 11.09 | (1.09) | |
Quick Ratio |
4.15 | 3.50 | 2.53 | 2.15 | |
Current Ratio |
4.25 | 3.59 | 2.58 | 2.20 | |
Net Debt/EBITDA |
43.05 | 10.92 | 11.95 | 65.30 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.45 | 0.40 | 0.39 | 0.31 | |
Operating CF/Net income |
2.94 | 2.34 | (0.19) | 1.07 | |
Capex/Depreciation |
(0.06) | (1.62) | (0.29) | 0.00 | |
Research and Development Expense of Revenue |
77.89% | 156.80% | 132.41% | 75.11% | |
Selling, General and Administrative Expense of Revenue |
40.79% | 54.78% | 54.07% | 35.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
8.55% | 17.48% | 21.41% | 5.89% | |
Graham Net Nets |
0.34 | 0.46 | 0.34 | (0.15) | |
Graham Number |
0.00 | 0.00 | 0.00 | 12.69 | |
Earnings Yield |
(15.56%) | (40.45%) | (59.63%) | (77.15%) | |
Free Cash Flow Yield |
(32.96%) | (41.73%) | (7.36%) | (14.48%) | |
Revenue per Share |
0.96 | 0.77 | 1.64 | 1.85 | |
Operating CF per Share |
(0.97) | (1.37) | (0.24) | (1.70) | |
Capex per Share |
0.00 | (0.03) | (0.01) | 0.00 | |
Free Cash Flow per Share |
(0.97) | (1.40) | (0.25) | (1.70) | |
Cash per Share |
7.01 | 9.20 | 16.45 | 10.08 | |
Shareholders Equity per Share |
3.72 | 4.44 | 4.22 | (0.79) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.72 | 4.44 | 4.22 | (0.79) | |
Free Cash Flow |
(18.78) | (22.90) | (2.09) | (17.49) | |
Working Capital |
111.27 | 111.25 | 88.75 | 67.69 | |
Capital Expenditures |
(0.02) | (0.56) | (0.09) | 0.00 | |
Net Current Asset Value |
63.48 | 63.27 | 25.62 | (17.70) | |
EV/EBIT |
0.00 | 0.27 | 1.46 | 0.00 | |
Capex to Sales |
0.00 | 0.04 | 0.01 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
3.21 | 1.67 | 2.87 | 1.64 | |
Average Assets |
144.03 | 133.60 | 112.88 | 104.18 | |
Average Common Equity |
39.67 | 41.62 | 26.44 | 6.44 |
Columns are period end dates